Business
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
SAN CARLOS, Calif., December 07, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":28492,"height":5743,"url":"https://media.zenfs.com/en/business-wire.com/7d78adefacfc42bb6da953d665d2ba21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5d2GBA_3wedA7HEFK6WleA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7d78adefacfc42bb6da953d665d2ba21","width":960,"height":194},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/m_1qJmVBHXJJgP12fUbIeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7d78adefacfc42bb6da953d665d2ba21","width":1200,"height":242}},"lazy":false},{"type":"text","content":"Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features","length":131,"tagName":"p","attribs":{}},{"type":"text","content":"SAN CARLOS, Calif., December 07, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine.","length":878,"tagName":"p"},{"type":"text","content":""The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor," said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne. "Our data demonstrates that sonrotoclax has succeeded where others have failed, ...